吉非替尼治疗非小细胞肺癌的疗效及对血清中表皮生长因子受体的影响

The effect and the expression of EGFR by gefitinib in patients with non small cell lung carcinoma

目的探讨吉非替尼佐治非小细胞肺癌的临床疗效,并观察治疗后血清中表皮生长因子受体(EGFR)的表达,以期为临床工作提供支持。方法收集我院确诊的112例非小细胞肺癌患者,依患者的入院顺序分为观察组与对照组,观察组共56例,应用吉非替尼治疗;对照组共56例,应用常规化疗,观察治疗的效果及治疗后血清中EGFR的差别。结果观察组的疗效明显优于对照组,治疗后观察组患者血清中EGFR的表达明显低于对照组。结论吉非替尼治疗非小细胞肺癌效果较好,并能有效下调血清中EGFR的表达,临床中可以积极应用。

Objective To observe the curative effect and EGFR change by gefitinib in patients with non small cell lung carcinoma for accumulating clinical experience and directing clinical treatment. Methods All of 112 patients were divided into two groups. The control group （56 cases） were treated by normal chemotherapy, and the observation group （56 cases） were treated by gefitiuib. We observed the efficacy and the change of EGFR in two groups. Results The total effective rate was obviously higher in the observation group than in the control group. The change value of EGFR were obviously higher in the observation group after treatment. Conclusion The treatment of gefitinib can improve the curative effect, regulate the expression of EGFR in patients with non small cell lung carcinoma, is worthy be recommended in clinical treatment.